Cargando…

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

Everolimus (RAD001, Afinitor(®) Novartis) is the first oral inhibitor of mTOR (mammalian target of rapamycin) to reach the oncology clinic. Everolimus 10 mg daily achieves complete inhibition of its target at below the maximum tolerable dose for most patients. A phase III randomized placebo-controll...

Descripción completa

Detalles Bibliográficos
Autor principal: Coppin, Chris
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880340/
https://www.ncbi.nlm.nih.gov/pubmed/20531964

Ejemplares similares